药物不良反应杂志
藥物不良反應雜誌
약물불량반응잡지
ADVERSE DRUG REACTIONS JOURNAL
2013年
6期
306-313
,共8页
西格列汀%糖尿病,2型%Meta分析
西格列汀%糖尿病,2型%Meta分析
서격렬정%당뇨병,2형%Meta분석
Sitagliptin%Diabetes mellitus,type 2%Meta-analysis
目的 对西格列汀治疗2型糖尿病的疗效和安全性进行评价. 方法 以“sitagliptin”为关键词检索PubMed、Embase及Cochrane Library,以“西格列汀”为关键词检索万方数据库,收集以糖化血红蛋白＜7％和不良反应发生率为研究终点的西格列汀治疗2型糖尿病的随机对照试验(RCT),对符合纳入标准的RCT进行质量评价,提取相关资料并应用RevMan 5.2软件进行统计分析,计算比值比(OR)和95％置信区间(CI). 结果 共25个RCT入选.Meta分析显示,西格列汀糖化血红蛋白＜7％达标率优于安慰剂(OR=3.02,95％ CI为2.48～3.67,P=0.00),逊于噻唑烷二酮类药物(OR =0.60,95％ CI为0.41～0.88,P=0.01),类似于二甲双胍(OR=0.78,95％CI为0.51 ～1.19,P=0.25)、胰高血糖素样肽1(GLP-1)受体激动剂(OR=0.53,95％ CI为0.15 ～1.92,P=0.34)和磺酰脲类药物(OR=0.93,95％ CI为0.58～1.48,P=0.76);不良反应发生率类似于安慰剂(OR=1.11,95％ CI为0.89 ～ 1.39,P=0.33),低于二甲双胍(OR=0.42,95％ CI为0.32～0.55,P=0.00)、噻唑烷二酮类药物(OR=0.65,95％ CI为0.45 ～ 0.94,P=0.02)、GLP-1受体激动剂(OR=0.45,95％CI为0.24～0.83,P=0.01)、磺酰脲类药物(OR=0.38,95％ CI为0.32 ～0.47,P=0.00). 结论 西格列汀治疗2型糖尿病可有效降低患者糖化血红蛋白水平,不良反应发生率低于其他降糖药.
目的 對西格列汀治療2型糖尿病的療效和安全性進行評價. 方法 以“sitagliptin”為關鍵詞檢索PubMed、Embase及Cochrane Library,以“西格列汀”為關鍵詞檢索萬方數據庫,收集以糖化血紅蛋白＜7％和不良反應髮生率為研究終點的西格列汀治療2型糖尿病的隨機對照試驗(RCT),對符閤納入標準的RCT進行質量評價,提取相關資料併應用RevMan 5.2軟件進行統計分析,計算比值比(OR)和95％置信區間(CI). 結果 共25箇RCT入選.Meta分析顯示,西格列汀糖化血紅蛋白＜7％達標率優于安慰劑(OR=3.02,95％ CI為2.48～3.67,P=0.00),遜于噻唑烷二酮類藥物(OR =0.60,95％ CI為0.41～0.88,P=0.01),類似于二甲雙胍(OR=0.78,95％CI為0.51 ～1.19,P=0.25)、胰高血糖素樣肽1(GLP-1)受體激動劑(OR=0.53,95％ CI為0.15 ～1.92,P=0.34)和磺酰脲類藥物(OR=0.93,95％ CI為0.58～1.48,P=0.76);不良反應髮生率類似于安慰劑(OR=1.11,95％ CI為0.89 ～ 1.39,P=0.33),低于二甲雙胍(OR=0.42,95％ CI為0.32～0.55,P=0.00)、噻唑烷二酮類藥物(OR=0.65,95％ CI為0.45 ～ 0.94,P=0.02)、GLP-1受體激動劑(OR=0.45,95％CI為0.24～0.83,P=0.01)、磺酰脲類藥物(OR=0.38,95％ CI為0.32 ～0.47,P=0.00). 結論 西格列汀治療2型糖尿病可有效降低患者糖化血紅蛋白水平,不良反應髮生率低于其他降糖藥.
목적 대서격렬정치료2형당뇨병적료효화안전성진행평개. 방법 이“sitagliptin”위관건사검색PubMed、Embase급Cochrane Library,이“서격렬정”위관건사검색만방수거고,수집이당화혈홍단백＜7％화불량반응발생솔위연구종점적서격렬정치료2형당뇨병적수궤대조시험(RCT),대부합납입표준적RCT진행질량평개,제취상관자료병응용RevMan 5.2연건진행통계분석,계산비치비(OR)화95％치신구간(CI). 결과 공25개RCT입선.Meta분석현시,서격렬정당화혈홍단백＜7％체표솔우우안위제(OR=3.02,95％ CI위2.48～3.67,P=0.00),손우새서완이동류약물(OR =0.60,95％ CI위0.41～0.88,P=0.01),유사우이갑쌍고(OR=0.78,95％CI위0.51 ～1.19,P=0.25)、이고혈당소양태1(GLP-1)수체격동제(OR=0.53,95％ CI위0.15 ～1.92,P=0.34)화광선뇨류약물(OR=0.93,95％ CI위0.58～1.48,P=0.76);불량반응발생솔유사우안위제(OR=1.11,95％ CI위0.89 ～ 1.39,P=0.33),저우이갑쌍고(OR=0.42,95％ CI위0.32～0.55,P=0.00)、새서완이동류약물(OR=0.65,95％ CI위0.45 ～ 0.94,P=0.02)、GLP-1수체격동제(OR=0.45,95％CI위0.24～0.83,P=0.01)、광선뇨류약물(OR=0.38,95％ CI위0.32 ～0.47,P=0.00). 결론 서격렬정치료2형당뇨병가유효강저환자당화혈홍단백수평,불량반응발생솔저우기타강당약.
Objective To assess the efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus.Methods PubMed,Embase,the Cochrane Library,and Wanfang Database was searched by using "sitagliptin" as keyword.Randomized controlled trials (RCT),whose endpoints were the level of glycosylated hemoglobin lower than 7％ and adverse reactions rates,of sitagliptin in the patients with type 2 diabetes mellitus were collected.The qualities of the RCT which could accord with inclusion criteria were evaluated.The related information was selected and statistically analyzed with RevMan 5.2 software and the odds ratio (OR) and 95％ confidence intervals (CI) were calculated.Results A total of 25 RCT were entered.Meta-analysis showed the control rate of glycosylated hemoglobin lower than 7％ of sitagliptin is better than that of placebo (OR =3.02,95％ CI:2.48 to 3.67,P =0.00),worse than that of thiazolidinedione (OR =0.60,95％ CI:0.41 to 0.88,P =0.01),and similar to that of merformin (OR =0.78,95％ CI:0.51 to 1.19,P =0.25),glucagon-like peptide (GLP-1) receptor agonists (OR =0.53,95％ CI:0.15 to 1.92,P =0.34),and sulfonylureas (OR =0.93,95％ CI:0.58 to 1.48,P =0.76).The adverse reactions rates of sitagliptin was similar with that of placebo (OR =1.11,95％ CI:0.89 to 1.39,P=0.33) and lower than that of merformin (OR =0.42,95％ CI:0.32 to 0.55,P =0.00),thiazolidinedione (OR =0.65,95 ％ CI:0.45 to 0.94,P =0.02),GLP-1 receptor agonists (OR =0.45,95 ％ CI:0.24to 0.83,P =0.01),and sulfonylureas (OR =0.38,95％CI:0.32 to 0.47,P =0.00).Conclusion Sitagliptin was effective in lowering the glycosylated hemoglobin level in the patients with type 2 diabetes mellitus and the adverse reaction rate of sitagliptin was lower than those of other antidiabetic drugs.
